Clinical Trial Results

« Previous 123 Next »
Viewing Page 1 of 3 | Showing Results 1 - 10 of 28

A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies

This trial will look at a drug called SGN-TGT to find out whether it is safe for patients with solid tumors and lymphomas. It will study SGN-TGT to...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients with Advanced Malignancies

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.This study will...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

HB-201 is an arenavirus vector-based vaccine expressing the inactivated fusion protein HPV 16 E7E6. This is a first in human (FIH) Phase I/II,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase Ia/Ib Open-label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

This is a Phase Ia/Ib, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I, first-in-human, dose-escalation study to evaluate the safety and immunologic response after administration of HS-130 in combination with HS-110 (viagenpumatucel-L) in patients with solid tumors refractory to standard care

This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis.

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced/Metastatic Solid Tumors who are refractory to Available Standard...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 123 Next »
Viewing Page 1 of 3 | Showing Results 1 - 10 of 28